Biopharmaceutical company Poolbeg Pharma announced findings from independent research confirming a substantial market opportunity exceeding $10bn for its drug candidate POLB 001 on Monday, in preventing cancer immunotherapy-induced cytokine release syndrome (CRS)

Cathal Friel, co-founder, substantial shareholder, and currently non-executive chairman of London-listed Poolbeg Pharma (AIM: POLB), is assuming the role of executive chairman at the company effective immediately. As executive chair

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively

Businessman Cathal Friel has become executive chairman of Poolbeg Pharma, the same job he had at Open Orphan (now hVivo) as that firm was developed. Mr Friel, a co-founder and

Poolbeg Pharma, a biopharmaceutical company specialising in the development and commercialisation of medicines targeting rare and orphan diseases, today announces that independent research conducted on its behalf confirms a >$10 billion market

Drugs like PARP inhibitors and chimeric antigen receptor (CAR) therapies, and advancements in artificial intelligence in drug discovery, have spurred hope for improved cancer care in the past year. Rigorous research

Big data is transforming everything from the way we drive to the way we shop or even the way we consume energy. But when it comes to healthcare and fighting

The future of drug discovery is no longer confined to the lab bench. It lies in the realm of intelligent algorithms, powerful computing, and the boundless creativity of generative AI.